APA (7th ed.) Citation

Garassino, M., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., Domine, M., . . . Rodríguez-Abreu, D. (2020). Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The lancet. Oncology, 21(3), . https://doi.org/10.1016/S1470-2045(19)30801-0

Chicago Style (17th ed.) Citation

Garassino, Marina, et al. "Patient-reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients with Previously Untreated, Metastatic, Non-squamous Non-small-cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-blind, Randomised, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology 21, no. 3 (2020). https://doi.org/10.1016/S1470-2045(19)30801-0.

MLA (9th ed.) Citation

Garassino, Marina, et al. "Patient-reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients with Previously Untreated, Metastatic, Non-squamous Non-small-cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-blind, Randomised, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology, vol. 21, no. 3, 2020, https://doi.org/10.1016/S1470-2045(19)30801-0.